Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie最新文献

筛选
英文 中文
Synthesis and biological evaluation of imidazolium conjugated with dimethylcardamonin (DMC) as a novel potential agent against MDA-MB-231 triple-negative breast cancer cells. 咪唑鎓与二甲基卡达莫宁(DMC)共轭物的合成与生物学评价,作为一种新型潜在制剂抗击 MDA-MB-231 三阴性乳腺癌细胞。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1016/j.biopha.2024.117249
Pornthip Chawapun, Nopawit Khamto, Kraikrit Utama, Sadanon Siriphong, Nathupakorn Dechsupa, Jiraporn Kantapan, Jomkhwan Meerak, Puttinan Meepowpan, Padchanee Sangthong
{"title":"Synthesis and biological evaluation of imidazolium conjugated with dimethylcardamonin (DMC) as a novel potential agent against MDA-MB-231 triple-negative breast cancer cells.","authors":"Pornthip Chawapun, Nopawit Khamto, Kraikrit Utama, Sadanon Siriphong, Nathupakorn Dechsupa, Jiraporn Kantapan, Jomkhwan Meerak, Puttinan Meepowpan, Padchanee Sangthong","doi":"10.1016/j.biopha.2024.117249","DOIUrl":"10.1016/j.biopha.2024.117249","url":null,"abstract":"<p><p>A new imidazolium ionic liquid (IL) halide conjugated with dimethylcardamonin (DMC, 1), namely [Bbim]Br-DMC (3), was synthesised to improve the biological activity of the natural chalcone. DMC was isolated from seeds of Syzygium nervosum A. Cunn. ex DC. which was an effective anti-breast cancer agent. The compound 1 and 3 showed anticancer activity in MDA-MB-231 cells with IC<sub>50</sub> values of 14.54 ± 0.99 μM and 7.40 ± 0.15 μM, respectively. MTT assay showed that compound 3 had cytotoxic effect at least two-fold greater than compound 1 but was low toxic to normal cells of Hs 578Bst. After 48 h, compound 3 at concentration of IC<sub>50</sub> value inhibited the proliferation and induced morphological changes of MDA-MB-231 cells in a time-dependent manner. The cell cycle profile also showed that compound 3 exerted anti-proliferation activity with the cell cycle arrest at G0/G1 phase and compound 3 also induced apoptosis and reduced mitochondrial membrane potential in MDA-MB-231 cells in a dose-dependent manner. In gene expression assay, compound 3 up-regulated pro-apoptotic genes such as Bax and p53 and suppressed anti-apoptotic Bcl-2 whereas there was no effect on DNA repair gene such as PARP1. The Bax/Bcl-2 ratio was significantly increased after treated with compound 3. In the molecular docking study, the interactions between compound 3 and B-DNA structure in the minor groove region via hydrogen bonds was reported. In conclusion, [Bbim]Br-DMC or compound 3 is a potential candidate to induce apoptosis and inhibits proliferation via cell cycle arrest and decreases mitochondrial membrane of triple-negative breast cancer MDA-MB-231 cells.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117249"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol treatment inhibits abnormal tumor growth by regulating neutrophil infiltration in a non-small cell lung carcinoma mouse model. 在非小细胞肺癌小鼠模型中,1-棕榈酰-2-亚油酰-3-乙酰-rac-甘油通过调节中性粒细胞浸润抑制肿瘤异常生长。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-12 DOI: 10.1016/j.biopha.2024.117269
Guentae Kim, Eun Young Kim, Hyowon Lee, Su-Hyun Shin, Se Hee Lee, Ki-Young Sohn, Jae Wha Kim, Jae Sam Lee
{"title":"1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol treatment inhibits abnormal tumor growth by regulating neutrophil infiltration in a non-small cell lung carcinoma mouse model.","authors":"Guentae Kim, Eun Young Kim, Hyowon Lee, Su-Hyun Shin, Se Hee Lee, Ki-Young Sohn, Jae Wha Kim, Jae Sam Lee","doi":"10.1016/j.biopha.2024.117269","DOIUrl":"10.1016/j.biopha.2024.117269","url":null,"abstract":"<p><p>Excessive neutrophil infiltration into the tumor microenvironment (TME) is an important factor that contributes to tumor overgrowth and limited immunotherapy efficacy. Neutrophils activate various receptors involved in tumor progression, while suppressing the infiltration and activity of cytotoxic T cells and creating optimal conditions for tumor growth. Therefore, the appropriate control of neutrophil infiltration is an effective strategy for tumor treatment. In the present study, 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) inhibited tumor overgrowth by suppressing excessive neutrophil infiltration, resulting in >74.97 % reduction in tumor size in a Lewis lung carcinoma (LLC-1) mouse model. All subjects in the positive control group died during the 90-day survival period, whereas only four subjects in the PLAG treatment group survived. PLAG had a significantly higher tumor growth inhibitory effect and survival rate than other neutrophil infiltration-targeting inhibitors (e.g., Navarixin, lymphocyte antigen 6 complex locus G6D antibody [aLy6G]). The ability of PLAG to regulate neutrophil infiltration and inhibit tumor growth depends on thioredoxin-interacting protein (TXNIP). In tumors lacking TXNIP expression, PLAG failed to control neutrophil infiltration and infiltration-related factor release, and the inhibitory effect of PLAG on tumor growth was reduced. PLAG-mediated inhibition of neutrophil infiltration enhances the efficacy of immune checkpoint inhibitors (ICIs), increasing the antitumor efficacy and survival rate by 30 %. In conclusion, PLAG could be a novel alternative to anti-tumor drugs that effectively targets excessive neutrophil infiltration into cancer tissues.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117269"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141977478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database. 基于 TCGA 数据库,将氟奋乃静重新定位为杯突症依赖性抗乳腺癌候选药物。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.1016/j.biopha.2024.117293
Xiaoli Zhang, Xiaoyuan Shi, Xi Zhang, Ying Zhang, Siting Yu, Yi Zhang, Yunfeng Liu
{"title":"Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database.","authors":"Xiaoli Zhang, Xiaoyuan Shi, Xi Zhang, Ying Zhang, Siting Yu, Yi Zhang, Yunfeng Liu","doi":"10.1016/j.biopha.2024.117293","DOIUrl":"10.1016/j.biopha.2024.117293","url":null,"abstract":"<p><p>Breast cancer is one of the most prevalent malignancies among women. Enhancing the prognosis is an effective approach to enhance the survival rate of breast cancer. Cuproptosis, a copper-dependent programmed cell death process, has been associated with patient prognosis. Inducing cuproptosis is a promising approach for therapy. However, there is currently no anti-breast cancer drug that induces cuproptosis. In this study, we repositioned the clinical drug fluphenazine as a potential agent for breast cancer treatment by inducing cuproptosis. Firstly, we utilized the Cancer Genome Atlas (TCGA) database and Connectivity Map (CMap) database to identify 22 potential compounds with anti-breast cancer activity through inducing cuproptosis. Subsequently, our findings demonstrated that fluphenazine effectively suppressed the viability of MCF-7 cells. Fluphenazine also significantly inhibited the viability of triple negative breast cancer cells MDA-MB-453 and MDA-MB-231. Furthermore, our study revealed that fluphenazine significantly down-regulated the expression of potential prognostic biomarkers associated with cuproptosis, increased copper ion levels, and reduced intracellular pyruvate accumulation. Additionally, it up-regulated the expression of FDX1 at both the mRNA and protein levels, which has been reported to play a crucial role in the induction of cuproptosis. These findings suggest that fluphenazine has the potential to be used as an anti-breast cancer drug by inducing cuproptosis. Therefore, this research provides an insight for the development of novel cuproptosis-dependent anti-cancer agents.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117293"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Schisandrol B inhibits calcification of aortic valve by targeting p53 related inflammatory and senescence. 五味子醇 B 通过靶向 p53 相关炎症和衰老抑制主动脉瓣钙化。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1016/j.biopha.2024.117241
Xing Liu, Kan Wang, Qiang Zheng, Xinyi Liu, Yuehang Yang, Chiyang Xie, Dingyi Yao, Chen Jiang, Zongtao Liu, Huadong Li, Jiawei Shi, Nianguo Dong
{"title":"Schisandrol B inhibits calcification of aortic valve by targeting p53 related inflammatory and senescence.","authors":"Xing Liu, Kan Wang, Qiang Zheng, Xinyi Liu, Yuehang Yang, Chiyang Xie, Dingyi Yao, Chen Jiang, Zongtao Liu, Huadong Li, Jiawei Shi, Nianguo Dong","doi":"10.1016/j.biopha.2024.117241","DOIUrl":"10.1016/j.biopha.2024.117241","url":null,"abstract":"<p><p>Calcific aortic valve disease (CAVD) primarily involves osteogenic differentiation in human aortic valve interstitial cells (hVICs). Schisandrol B (SolB), a natural bioactive constituent, has known therapeutic effects on inflammatory and fibrotic disorders. However, its impact on valve calcification has not been reported. We investigated the effect of SolB on osteogenic differentiation of hVICs. Transcriptome sequencing was used to analyze potential molecular pathways affected by SolB treatment. The study also included an in vivo murine model using aortic valve wire injury surgery to observe SolB's effect on valve calcification. SolB inhibited the osteogenic differentiation of hVICs, reversing the increase in calcified nodule formation and osteogenic proteins. In the murine model, SolB significantly decreased the peak velocity of the aortic valve post-injury and reduced valve fibrosis and calcification. Transcriptome sequencing identified the p53 signaling pathway as a key molecular target of SolB, demonstrating its role as a molecular glue in the mouse double minute 2 (MDM2)-p53 interaction, thereby promoting p53 ubiquitination and degradation, which further inhibited p53-related inflammatory and senescence response. These results highlighted therapeutic potential of SolB for CAVD via inhibiting p53 signaling pathway and revealed a new molecular mechanism of SolB which provided a new insight of theraputic mechanism for CAVD.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117241"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral matrine alleviates CCl4-induced liver fibrosis via preserved HSP72 from modulated gut microbiota. 通过调节肠道微生物群保存HSP72,口服马钱子碱可减轻CCl4诱导的肝纤维化。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1016/j.biopha.2024.117262
Junye Zhu, Bing Li, Weiming Fang, Xiu Zhou, Dongli Li, Jingwei Jin, Wu Li, Yibo Su, Ruinan Yuan, Ji-Ming Ye, Rihui Wu
{"title":"Oral matrine alleviates CCl4-induced liver fibrosis via preserved HSP72 from modulated gut microbiota.","authors":"Junye Zhu, Bing Li, Weiming Fang, Xiu Zhou, Dongli Li, Jingwei Jin, Wu Li, Yibo Su, Ruinan Yuan, Ji-Ming Ye, Rihui Wu","doi":"10.1016/j.biopha.2024.117262","DOIUrl":"10.1016/j.biopha.2024.117262","url":null,"abstract":"<p><p>Hepatic fibrosis is intricately associated with dysregulation of gut microbiota and host metabolomes. Our previous studies have demonstrated that matrine can effectively reduce hepatosteatosis and associated disorders. However, it is poorly understood whether the gut microbiota involved in the attenuation of liver fibrosis by matrine. Herein we explored a novel mechanism of how oral administration of matrine alleviates liver fibrosis by modulating gut microbiota. Administration of matrine not only potently ameliorated liver fibrosis in carbon tetrachloride (CCl4)-induced mice, but also significantly preserved hepatic heat shock protein 72 (HSP72) in vivo and in vitro. Matrine was failed to reduce liver fibrosis when HSP72 upregulation was blocked by the HSP72 antagonist VER-155008. Also, consumption of matrine significantly alleviated gut dysbiosis and fecal metabonomic changes in CCl4-treated mice. Transplanted the faces of matrine-treated mice induced a remarkable upregulation of HSP72 and remission of fibrosis in liver in CCl4-exposed mice and inhibition of TGF-β1-induced inflammatory response and epithelial-mesenchymal transition (EMT) in AML-12 cells. Furthermore, deficiency of HSP72 partly reversed the intestinal microbial composition that prevented matrine from reducing CCl4-induced liver fibrosis in mice. This study reveals the \"gut microbiota-hepatic HSP72\" axis as a key mechanism of matrine in reducing liver fibrosis and suggest that this axis may be targeted for developing other new therapies for liver fibrosis.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117262"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pirfenidone improves early cardiac function following myocardial infarction by enhancing the elastin/collagen ratio. 吡非尼酮可通过提高弹性蛋白/胶原蛋白比率来改善心肌梗死后的早期心脏功能。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.1016/j.biopha.2024.117254
Yuexin Yu, Yaping Xu, Jinfu Chen, Yao Yao, Yingtian Liu, Yan Chen, Bin Yang, Zhikun Guo
{"title":"Pirfenidone improves early cardiac function following myocardial infarction by enhancing the elastin/collagen ratio.","authors":"Yuexin Yu, Yaping Xu, Jinfu Chen, Yao Yao, Yingtian Liu, Yan Chen, Bin Yang, Zhikun Guo","doi":"10.1016/j.biopha.2024.117254","DOIUrl":"10.1016/j.biopha.2024.117254","url":null,"abstract":"<p><strong>Background: </strong>Acute myocardial infarction (AMI) is a leading cause of mortality worldwide, with reduced elastin/collagen ratios exacerbating cardiac dysfunction due to collagen-rich scar tissue replacing necrotic myocardial cells. This study aims to evaluate pirfenidone's therapeutic effect on early cardiac function post-AMI and elucidate its impact on the elastin/collagen ratio.</p><p><strong>Methods: </strong>Sprague-Dawley rats were divided into four groups: Sham, AMI, AMI treated with PBS (AMI-PBS), and AMI treated with pirfenidone (AMI-PFD) (n=12 each). AMI was induced via coronary artery ligation. The AMI-PFD and AMI-PBS groups received pirfenidone and PBS for 14 days, respectively. Cardiac function, fibrosis, serum cytokines, collagen and elastin content, and their ratios were assessed. Cardiac fibroblasts (CFs) from neonatal rats were categorized into control, hypoxia-induced (LO), LO+PBS, and LO+PFD groups. ELISA measured inflammatory factors, and RT-PCR analyzed collagen and elastin gene expression.</p><p><strong>Results: </strong>The AMI-PFD group showed improved cardiac function and reduced serum interleukin-1β (IL-1β), IL-6, and transforming growth factor-β (TGF-β). Type I and III collagen decreased by 22.6 % (P=0.0441) and 34.4 % (P=0.0427), respectively, while elastin content increased by 79.4 % (P=0.0126). E/COLI and E/COLIII ratios rose by 81.1 % (P=0.0026) and 88.1 % (P=0.0006). CFs in the LO+PFD group exhibited decreased IL-1β, IL-6, TGF-β, type I and III collagen, with increased elastin mRNA, enhancing the elastin/collagen ratio.</p><p><strong>Conclusion: </strong>Pirfenidone enhances cardiac function by augmenting the early elastin/collagen ratio post-AMI.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117254"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formation mechanism, prevention of malignant ascites effusion and reduction of intestinal mucosal irritation of natural microemulsion from Euphorbia lathyris Pulveratum. 矢车菊天然微乳剂的形成机理、预防恶性腹水渗出和减少对肠粘膜的刺激
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1016/j.biopha.2024.117253
Huinan Wang, Mingrui Jiang, Siyuan Ma, Yufeng Hu, Xinning Zhang, Haiting Zhu, Junli Zhang, Yingzi Wang
{"title":"Formation mechanism, prevention of malignant ascites effusion and reduction of intestinal mucosal irritation of natural microemulsion from Euphorbia lathyris Pulveratum.","authors":"Huinan Wang, Mingrui Jiang, Siyuan Ma, Yufeng Hu, Xinning Zhang, Haiting Zhu, Junli Zhang, Yingzi Wang","doi":"10.1016/j.biopha.2024.117253","DOIUrl":"10.1016/j.biopha.2024.117253","url":null,"abstract":"<p><p>Malignant ascites effusion (MAE) is a common complication of advanced malignant tumors with limited treatments. Euphorbia lathyris (EL) has a long history of application in patients with edema and ascites. Herein, we reported for the first time a mode in which EL and EL Pulveratum (PEL) spontaneously formed natural microemulsions (ELM and PELM) without the addition of any carriers and excipients, and found that the protein and phospholipid contained in them encapsulated fatty oil and diterpenoid esters through non-covalent interactions. The denaturation and degradation of protein in PELM resulted in stronger binding of diterpenoid esters to the hydrophobic region of protein, which facilitated the sustained and slow release of diterpenoid esters and improved their bioavailability in vivo, thereby retaining the efficacy of preventing MAE while alleviating the irritation of intestinal mucosa. The mechanism by which PELM retained efficacy might be related to increased feces moisture and urine volume, and decreased expression of AVPR2, cAMP, PKA and AQP3 in MAE mice. And its mechanism of reducing intestinal mucosal irritation was related to decreased cell apoptosis, amelioration of oxidative stress, elevation of mitochondrial membrane potential, and up-regulation of Occludin and Claudin-1 expression in IEC-6 cells. This nano-adjuvant-free natural microemulsions may be a promising therapeutic strategy in the field of phytochemistry for promoting the application of natural and efficient nano-aggregates spontaneously formed by medicinal plants in MAE, and provide a new perspective for advancing the development of the fusion of Chinese herbal medicine and nanomedicine and its clinical translation.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117253"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-induced pulmonary fibrosis and related lung stiffness. 诱导多能干细胞衍生的间充质干细胞可逆转博莱霉素诱导的肺纤维化和相关的肺僵化。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-07 DOI: 10.1016/j.biopha.2024.117259
Amlan Chakraborty, Chao Wang, Margeaux Hodgson-Garms, Brad R S Broughton, Jessica E Frith, Kilian Kelly, Chrishan S Samuel
{"title":"Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-induced pulmonary fibrosis and related lung stiffness.","authors":"Amlan Chakraborty, Chao Wang, Margeaux Hodgson-Garms, Brad R S Broughton, Jessica E Frith, Kilian Kelly, Chrishan S Samuel","doi":"10.1016/j.biopha.2024.117259","DOIUrl":"10.1016/j.biopha.2024.117259","url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis (IPF) is characterised by lung scarring and stiffening, for which there is no effective cure. Based on the immunomodulatory and anti-fibrotic effects of induced pluripotent stem cell (iPSC) and mesenchymoangioblast-derived mesenchymal stem cells (iPSCs-MSCs), this study evaluated the therapeutic effects of iPSCs-MSCs in a bleomycin (BLM)-induced model of pulmonary fibrosis. Adult male C57BL/6 mice received a double administration of BLM (0.15 mg/day) 7-days apart and were then maintained for a further 28-days (until day-35), whilst control mice were administered saline 7-days apart and maintained for the same time-period. Sub-groups of BLM-injured mice were intravenously-injected with 1×10<sup>6</sup> iPSC-MSCs on day-21 alone or on day-21 and day-28 and left until day-35 post-injury. Measures of lung inflammation, fibrosis and compliance were then evaluated. BLM-injured mice presented with lung inflammation characterised by increased immune cell infiltration and increased pro-inflammatory cytokine expression, epithelial damage, lung transforming growth factor (TGF)-β1 activity, myofibroblast differentiation, interstitial collagen fibre deposition and topology (fibrosis), in conjunction with reduced matrix metalloproteinase (MMP)-to-tissue inhibitor of metalloproteinase (TIMP) ratios and dynamic lung compliance. All these measures were ameliorated by a single or once-weekly intravenous-administration of iPSC-MSCs, with the latter reducing dendritic cell infiltration and lung epithelial damage, whilst promoting anti-inflammatory interleukin (IL)-10 levels to a greater extent. Proteomic profiling of the conditioned media of cultured iPSC-MSCs that were stimulated with TNF-α and IFN-γ, revealed that these stem cells secreted protein levels of immunosuppressive factors that contributed to the anti-fibrotic and therapeutic potential of iPSCs-MSCs as a novel treatment option for IPF.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117259"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141908672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of angiogenesis by the secretome from iPSC-derived retinal ganglion cells with Leber's hereditary optic neuropathy-like phenotypes. 具有类似 Leber 遗传性视神经病变表型的 iPSC 衍生视网膜神经节细胞分泌物抑制血管生成。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-11 DOI: 10.1016/j.biopha.2024.117270
Shih-Yuan Peng, Chih-Ying Chen, Hsin Chen, Yi-Ping Yang, Mong-Lien Wang, Fu-Ting Tsai, Chian-Shiu Chien, Pei-Yu Weng, En-Tung Tsai, I-Chieh Wang, Chih-Chien Hsu, Tai-Chi Lin, De-Kuang Hwang, Shih-Jen Chen, Shih-Hwa Chiou, Chuan-Chin Chiao, Yueh Chien
{"title":"Inhibition of angiogenesis by the secretome from iPSC-derived retinal ganglion cells with Leber's hereditary optic neuropathy-like phenotypes.","authors":"Shih-Yuan Peng, Chih-Ying Chen, Hsin Chen, Yi-Ping Yang, Mong-Lien Wang, Fu-Ting Tsai, Chian-Shiu Chien, Pei-Yu Weng, En-Tung Tsai, I-Chieh Wang, Chih-Chien Hsu, Tai-Chi Lin, De-Kuang Hwang, Shih-Jen Chen, Shih-Hwa Chiou, Chuan-Chin Chiao, Yueh Chien","doi":"10.1016/j.biopha.2024.117270","DOIUrl":"10.1016/j.biopha.2024.117270","url":null,"abstract":"<p><p>The blood supply in the retina ensures photoreceptor function and maintains regular vision. Leber's hereditary optic neuropathy (LHON), caused by the mitochondrial DNA mutations that deteriorate complex I activity, is characterized by progressive vision loss. Although some reports indicated retinal vasculature abnormalities as one of the comorbidities in LHON, the paracrine influence of LHON-affected retinal ganglion cells (RGCs) on vascular endothelial cell physiology remains unclear. To address this, we established an in vitro model of mitochondrial complex I deficiency using induced pluripotent stem cell-derived RGCs (iPSC-RGCs) treated with a mitochondrial complex I inhibitor rotenone (Rot) to recapitulate LHON pathologies. The secretomes from Rot-treated iPSC-RGCs (Rot-iPSC-RGCs) were collected, and their treatment effect on human umbilical vein endothelial cells (HUVECs) was studied. Rot induced LHON-like characteristics in iPSC-RGCs, including decreased mitochondrial complex I activity and membrane potential, and increased mitochondrial reactive oxygen species (ROS) and apoptosis, leading to mitochondrial dysfunction. When HUVECs were exposed to conditioned media (CM) from Rot-iPSC-RGCs, the angiogenesis of HUVECs was suppressed compared to those treated with CM from control iPSC-RGCs (Ctrl-iPSC-RGCs). Angiogenesis-related proteins were altered in the secretomes from Rot-iPSC-RGC-derived CM, particularly angiopoietin, MMP-9, uPA, collagen XVIII, and VEGF were reduced. Notably, GeneMANIA analysis indicated that VEGFA emerged as the pivotal angiogenesis-related protein among the identified proteins secreted by health iPSC-RGCs but reduced in the secretomes from Rot-iPSC-RGCs. Quantitative real-time PCR and western blots confirmed the reduction of VEGFA at both transcription and translation levels, respectively. Our study reveals that Rot-iPSC-RGCs establish a microenvironment to diminish the angiogenic potential of vascular cells nearby, shedding light on the paracrine regulation of LHON-affected RGCs on retinal vasculature.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117270"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to: "Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D" [Biomed. Pharmacother. 150 (2022) 1-11]. 更正:"用大剂量维生素 D 治疗严重 COVID-19 患者对 SARS-CoV-2 的免疫反应的变化》[Biomed. Pharmacother. 150 (2022) 1-11]。
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-03 DOI: 10.1016/j.biopha.2024.117251
Montserrat Torres, Guiomar Casado, Lorena Vigón, Sara Rodríguez-Mora, Elena Mateos, Fernando Ramos-Martín, Daniel López-Wolf, José Sanz-Moreno, Pablo Ryan-Murua, María Luisa Taboada-Martínez, María Rosa López-Huertas, Miguel Cervero, Mayte Coiras
{"title":"Corrigendum to: \"Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D\" [Biomed. Pharmacother. 150 (2022) 1-11].","authors":"Montserrat Torres, Guiomar Casado, Lorena Vigón, Sara Rodríguez-Mora, Elena Mateos, Fernando Ramos-Martín, Daniel López-Wolf, José Sanz-Moreno, Pablo Ryan-Murua, María Luisa Taboada-Martínez, María Rosa López-Huertas, Miguel Cervero, Mayte Coiras","doi":"10.1016/j.biopha.2024.117251","DOIUrl":"10.1016/j.biopha.2024.117251","url":null,"abstract":"","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":" ","pages":"117251"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信